Skip to main content
OpenTrials
Completed

NCT Number: NCT04434157

Association of the Neutrophil/Lymphocyte Ratio With Clinical Complications and Mortality in COVID-19 Patients

There is little information about the clinical characteristics and risk factors of Covid-19 in Latin American countries considering the ethnic differences and the high prevalence of obesity and cardiometabolic diseases. The aim of the study was to evaluate the association between laboratory tests and the risk of complications in SARS-CoV-2 infection and to determine their mortality risk factors in a sample of the Mexican population.

A retrospective cross-sectional study of the routinely collected data was performed in the Hospital Regional de Alta Especialidad de Ixtapaluca (HRAEI), State of Mexico. Adult patients (aged ≥18 years) with positive RT-PCR for SARS-CoV-2 and oxygen support that were admitted between March 28 and May 5, 2020, were included

Completed

Looking for future studies?

Notify Me

Key information

Sex eligibility

All sexes

Study type

Observational

Primary location

Hospital Regional de Alta Especialidad de Ixtapaluca

Ixtapaluca, State of Mexico, 56530, Mexico

About this study

Data collection Data was collected deidentified admission from adult patients, with oxygen therapy. Data were extracted from clinical medical records and the electronic database of daily laboratory test results. Also, incomplete clinical records were included. The number of cases in the area during the study period determined the sample size, no formal hypotheses being implemented. All patients who met the inclusion criteria were included.

Study variables Demographic variables (sex and age), chronic medical histories (hypertension, diabetes and cancer), laboratory plasma, and serum-based biomarkers, as well as the mortality, mechanical ventilation, and length of stay, were considered. Leukocytosis was considered as a leucocyte count above 10 x 103/mcL, a cut point of INL> 10, d- dimer 500 U/L, DHL> 500U/L, low count of lymphocytes < 0·5103/mcL as risk factors exposure to death and mechanical ventilation.

A new variable was create combining the data of neutrophil count (ANC) and lymphocyte count (ALC) to obtain the neutrophil-to-lymphocyte ratio (NLR) (calculated dividing the ANC by the ALC).

Outcomes The hypothesis was formulated before the statistical analysis. Our primary outcomes were to 1) To describe the clinical characteristics of the Mexican population with SARS-CoV-2 infection, and 2) To determine the mortality risk factors in Covid-19.

Secondary outcomes included 1) To identify the chronic diseases related to Covid-19 in Mexican population and 2) To evaluate the differences in hematic and biochemical parameters between survivors and no survivors.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult patients (aged ≥18 years)
  • Clinical (Positive RT-PCR for SARS-CoV-2 test) and radiological diagnosis of pulmonary infection by COVID-19
  • Diagnosis of acute respiratory distress syndrome clinical panel in accordance with Berlin 2012 criteria
  • Need of non-invasive ventilation (NIV or CPAP) or invasive ventilation (intubation)

Exclusion criteria

  • Previous diagnosis of severe liver or kidney failure.
  • Patients with Human Immunodeficiency Virus (HIV) infection.
  • Patients with previous hematological diseases (Leukemia) that condition alterations in blood counts.
  • Consumption of treatments with any type of immunosuppressants prior to admission that conditions low lymphocytes.
  • Patients with a diagnosis of active or non-active cancer.
  • Absence of a clinical record for monitoring the data.
  • Pregnancy.
  • Patients referred from other institutions for their medical care. Clinical records of patients who requested their voluntary discharge Clinical records that do not include information of the course of COVID-19 infection

Treatment and study plan

Primary outcomes

  1. Clinical complications and Mortality

    Time frame: 10 days

    To main aim of the study is to evaluate clinical complicatios and mortality in mexican Covid-19 patients

  2. Neutrophil-Lymphocyte and Lymphocyte-Platelet ratio

    Time frame: 10 days

    To evaluate the association of the hematological ratios with the clinical complicatios and mortality in covid-19 patinets

Other outcomes

  1. Hematic and biochemical parameters

    Time frame: 10 days

    To evaluate the differences in hematic and biochemical parameters between survivors and no survivors

  2. Chronic diseases

    Time frame: 10 days

    To identify the chronic diseases in the patientss´medical records associated with the pulmonary complications

Sponsors and collaborators

Lead sponsor

Hospital Regional de Alta especialidad de Ixtapaluca

Other

Collaborators

  • Hospital General de México Dr. Eduardo Liceaga

Registry information

Official study title

Association of the Neutrophil/Lymphocyte Ratio and Lymphocyte /Platelet Ratio With Clinical Complications and Mortality in COVID-19 Patients

Important dates

Study start
2020
Primary completion
2020
Study completion
2020
First posted
Jun 16, 2020
Registry last updated
Jun 16, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.